Novelix Pharmaceuticals Plans ₹6.84 Crore Preferential Issue

Proposed Issue Size: 1,200,000 Equity Shares
Issue Price: ₹57 per share

Reader Takeaway: Raising capital for expansion; watch for dilution and execution variances.

What just happened

Novelix Pharmaceuticals Ltd announced a preferential issue of 1,200,000 equity shares at a price of ₹57 per share, aiming to raise an aggregate of ₹6.84 crore (₹684 lakh). The company has scheduled an Extraordinary General Meeting (EGM) on July 01, 2026, to seek shareholder approval for this move. The issue is proposed to be made to non-promoters.

Why this matters

The funds raised will be crucial for Novelix Pharmaceuticals' expansion plans. Key utilization areas include lab-scale technology transfer fees (₹75 lakh), deposit for land lease (₹100 lakh), land development (₹188 lakh), consumables (₹100 lakh), travel for technical experts (₹35 lakh), pre-operative expenses (₹125 lakh), and quality control equipment (₹61 lakh). This capital infusion is intended to support the company's growth initiatives.

The backstory

This preferential issue follows a similar corporate action by the company. Novelix Pharmaceuticals had previously completed a preferential allotment of 2,810,000 equity shares on May 29, 2026, at an issue price of ₹20 per share. The current issue's price of ₹57 per share signifies a significant premium over the previous allotment.

What changes now

Shareholders will vote on this preferential issue at the EGM on July 1, 2026. Approval will lead to the issuance of new equity shares to non-promoters, thereby increasing the company's capital base. The company has emphasized that the pricing complies with SEBI (ICDR) Regulations, 2018, based on the volume-weighted average price.

Risks to watch

Two key points require investor attention. Firstly, the preferential allotment to non-promoters will lead to dilution, reducing the existing shareholders' percentage ownership in the company. Secondly, there is an execution risk related to the utilization of proceeds. The company has noted that the stated utilization amounts are estimates and may vary by +/- 10% due to market conditions.

Peer comparison

As of the latest available information, direct peer comparison for specific capital utilization plans like lab-scale tech transfer fees and land lease deposits is not readily available. However, pharmaceutical companies often raise capital for R&D, manufacturing expansion, and working capital needs.

Context metrics

The issue price of ₹57 per share is a significant premium to the face value of ₹10 per equity share. The total aggregate amount being raised is ₹6.84 crore.

What to track next

Investors should closely monitor the outcome of the EGM on July 1, 2026. Following the EGM, tracking the actual timeline and expenditure against the proposed utilization of funds will be crucial. The company's adherence to its estimated budget for expansion activities and management of shareholder dilution are key factors to observe.